| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
The primary target of paederosidic acid methyl ester is the ATP-sensitive K⁺ channel. By activating these channels in the brain and spinal cord, the compound exerts central analgesic effects. The antinociceptive action is also related to the NO-cGMP pathway. The compound may also exhibit anti-inflammatory, antioxidant, and antimicrobial properties.
|
|---|---|
| ln Vitro |
In vitro, paederosidic acid methyl ester acts as an ATP-sensitive K⁺ channel activator. Its activity has been characterized in channel activation assays. The compound's antinociceptive effects have been demonstrated in various in vitro models. It may also exhibit anti-inflammatory, antioxidant, and antimicrobial properties.
|
| ln Vivo |
In vivo, paederosidic acid methyl ester exhibits significant central analgesic activity in mice using chemical and thermal models of nociception. It enhances the threshold of pain by activating ATP-sensitive K⁺ channels in the brain and spinal cord. The compound's antinociceptive action is possibly related to the NO-cGMP-ATP sensitive K⁺ channel pathway.
|
| Enzyme Assay |
For in vitro channel activation assays, paederosidic acid methyl ester is tested on cells expressing ATP-sensitive K⁺ channels. Cells are treated with varying concentrations of the compound, and channel activity is measured using patch-clamp electrophysiology or fluorescence-based membrane potential assays. The compound's ability to activate K⁺ channels is determined by measuring changes in membrane potential or potassium flux.
|
| Cell Assay |
For in vitro cell-based assays, paederosidic acid methyl ester is typically tested on neuronal cell lines. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-48 hours. Cell viability is assessed using MTT assays. Neuronal activity or signaling pathway modulation (NO-cGMP pathway) can be assessed by measuring cGMP levels or using specific inhibitors.
|
| Animal Protocol |
For in vivo animal experiments, paederosidic acid methyl ester is typically administered orally or intraperitoneally to mice. Nociception is assessed using chemical models (such as acetic acid-induced writhing or formalin test) and thermal models (such as hot plate test or tail flick test). The compound's antinociceptive effect is evaluated by measuring the reduction in pain responses. The involvement of ATP-sensitive K⁺ channels is confirmed using channel blockers such as glibenclamide.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for paederosidic acid methyl ester are limited. As an iridoid glycoside with a molecular weight of 478.47 g/mol and formula C₁₉H₂₆O₁₂S, it is expected to have moderate oral bioavailability. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for paederosidic acid methyl ester are limited. As a natural product isolate, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Reports indicate that methyl paederosidic acid has been found in Paederia scandens and Paederia foetida, and relevant data are available for reference.
Paederosidic acid methyl ester is a research-use only compound and has not been approved for clinical applications. It is an iridoid glycoside from Paederia scandens. Its molecular weight is 478.47 and formula is C₁₉H₂₆O₁₂S. It is available from various research chemical suppliers. |
| Molecular Formula |
C19H26O12S
|
|---|---|
| Molecular Weight |
478.4675
|
| Exact Mass |
478.114
|
| CAS # |
122413-01-8
|
| PubChem CID |
6325269
|
| Appearance |
White to light yellow solid
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
711.2±70.0 °C at 760 mmHg
|
| Flash Point |
383.9±35.7 °C
|
| Vapour Pressure |
0.0±5.2 mmHg at 25°C
|
| Index of Refraction |
1.634
|
| LogP |
-1.72
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
769
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
S(C([H])([H])[H])C(=O)OC([H])([H])C1=C([H])[C@@]([H])([C@@]2([H])C(C(=O)OC([H])([H])[H])=C([H])O[C@]([H])([C@@]21[H])O[C@@]1([H])[C@@]([H])([C@@]([H])([C@@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])O[H]
|
| InChi Key |
JNDNZIPLLDTLQK-DILZHRMZSA-N
|
| InChi Code |
InChI=1S/C19H26O12S/c1-27-16(25)8-6-28-17(31-18-15(24)14(23)13(22)10(4-20)30-18)11-7(3-9(21)12(8)11)5-29-19(26)32-2/h3,6,9-15,17-18,20-24H,4-5H2,1-2H3/t9-,10+,11+,12-,13+,14-,15+,17-,18-/m0/s1
|
| Chemical Name |
methyl (1S,4aS,5S,7aS)-5-hydroxy-7-(methylsulfanylcarbonyloxymethyl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~209.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0900 mL | 10.4500 mL | 20.9000 mL | |
| 5 mM | 0.4180 mL | 2.0900 mL | 4.1800 mL | |
| 10 mM | 0.2090 mL | 1.0450 mL | 2.0900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
